news

Announcements and Updates


TOLREMO raises CHF 9 million series A financing round and strengthens Board of Directors with industry experts

Zurich, September 24th 2018. TOLREMO therapeutics AG (“TOLREMO”), a privately held Swiss biotech company, announced today the completion of an oversubscribed series A financing round of CHF 9.0 million (USD $9.3 million). The Swiss venture capital firm BioMedPartners led the round and was joined by the Swiss venture capital firms Redalpine and Altos Venture, as well as TOLREMO’s existing shareholders including the Swiss bank Zürcher Kantonalbank and several experienced biotech investors. The capital increase will allow the ETH Spin-off to further advance two major drug development programs to prevent drug resistance in cancer therapies.

Read More
Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a Swiss clinical-stage biopharmaceutical company, announced today that it has successfully raised additional financing of CHF 6 million from existing shareholders and several new private investors. The financing raised via a rights offering, with pro-rata rights for existing shareholders, was significantly oversubscribed. The proceeds of the financing will be used to prepare for a global Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP).

Read More
Isaac Kobrin
Novaremed announces that it has raised CHF 4.4 million Phase 2b study planned for lead compound NRD.E1 in diabetic neuropathic pain

Basel/Switzerland, April 17, 2018 – Novaremed AG, a newly incorporated Swiss clinical-stage biopharmaceutical company, announced today that it has successfully raised CHF 4.44 million from private investors. The funds will be used to prepare for a Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP).

Read More
Isaac KobrinNovaremed
TOLREMO therapeutics AG – Preventing Drug Resistance in Cancer Therapy

Zurich, September 18th 2017. TOLREMO therapeutics AG (“TOLREMO”), a privately held research-stage biotechnology company, announced today the completion of a fundraiser with private investors of 2.4 million Swiss Francs. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.

Read More
Virometix Appoints Dr. Pierre A. Morgon as New Chairman and Dr. Isaac Kobrin as New Member of the Board of Virometix AG

Schlieren, Switzerland  (25.01.2017) –  Virometix  today announced the appointment of Dr.  Pierre  A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments  Virometix  is taking further steps to enhance professional expertise within the Board of Directors and senior management of the company. Furthermore, the Scientific Advisory Board has been strengthened with the addition of emeritus Prof. Paul-Henri Lambert, MD.

Read More
Isaac KobrinVirometix AG